Immunotherapeutic approaches to treating Alzheimer's disease (AD) using vaccination strategies must overcome the obstacle of achieving adequate responses to vaccination in the elderly. Here we demonstrate for the first time that application of the Escherichia coli heat-labile enterotoxin adjuvant-laden immunostimulatory patches (LT-IS) dramatically enhances the onset and magnitude of immune responses to DNA-and proteinbased vaccines for Alzheimer's disease following intradermal immunization via gene gun and conventional needles, respectively. Our studies suggest that the immune activation mediated by LT-IS offers improved potency for generating AD-specific vaccination responses that should be investigated as an adjuvant in the clinical arena.
Introduction
Alzheimer's disease (AD) is characterized by dementia that typically begins with subtle and poorly recognized failure of memory that gradually becomes severe and incapacitating. Other common findings include confusion, poor judgment, language disturbance, agitation, withdrawal, and hallucinations (Brookmeyer et al., 2007) . The neuropathological features of the disease include neurofibrillary tangles (NFT), deposition of amyloid-β (Aβ) in senile plaques, and neuronal loss in affected brain regions (Price and Sisodia, 1994) . Based on the amyloid cascade hypothesis (Hardy and Higgins, 1992; Hardy and Selkoe, 2002) , many active and passive vaccination strategies directed toward reducing the Aβ deposits are currently being tested in clinical trials (Lemere and Masliah, 2010) . In the first AN-1792 clinical trial the vaccination led to the development of meningoencephalitis in some of the patients, which was believed to be associated with anti-Aβ specific T cell autoreactivity (Nicoll et al., 2003; Masliah et al., 2005) . Of note, only low titers of anti-Aβ antibodies were generated in the majority of AD patients, and there was a lack of measurable antibody responses in approximately 40% of the patients even after additional injections with modified formulations (Bayer et al., 2005 )-(Fox et al., 2005 . Hence, overcoming both safety issues and poor immunogenicity has evolved as being the primary barriers to successful immunotherapy for AD.
We have previously generated DNA-, peptide-and protein-based epitope vaccines composed of three copies of a self B-cell epitope of Aβ 42 (Aβ 11 or Aβ 12 ) and the foreign T helper (Th) cell epitope or string of multiple Th epitopes, collectively designated as universal MultiTEP platform. These prototype AD vaccines were found to be safe based on lack of induction of T cell autoreactivity, and were also highly immunogenic in wild-type mice, APP/Tg mice, rabbits and monkeys (Petrushina et al., 2007; Movsesyan et al., 2008; Davtyan et al., 2010 Davtyan et al., , 2013 Evans et al., 2013; Ghochikyan et al., 2013) . However, induction of immune responses in humans is more challenging and requires a potent adjuvant (in case of protein vaccines) or delivery system (in case of DNA vaccines) to induce potent Th responses and subsequently high titers of antibodies. Of note, the only conventional adjuvant approved by the FDA for protein vaccines are aluminum based adjuvants. On the other hand, the application of DNA immunization methods used in mice did not provide encouraging results in humans or large animals (Babiuk et al., 2003) although three types of veterinary DNA-based vaccines have been approved (Kutzler and Weiner, 2008) . Journal of Neuroimmunology 268 (2014) 50-57 
